The US Food and Drug Administration (FDA) has approved and issued Emergency Use Authorizations (EUAs) for some medications used to treat COVID-19 infection in non-hospitalized, high-risk individuals in outpatient settings, including early antiviral therapy for the treatment of mild to moderate COVID-19. These therapies have been authorized for individuals at highest risk for severe COVID-19 and disease progression, including those who may not be eligible for COVID-19 vaccination, have an underlying medical condition or are receiving therapies that are known to result in a poor antibody response to vaccination. Current evidence remains limited but is evolving regarding which underlying medical conditions in children definitively associate with higher risk for severe COVID-19 or disease progression. There continues to be a paucity of pediatric-specific data regarding the safety, efficacy and pharmacokinetics of these treatments across all pediatric age groups.
Please click on the link below to learn more about Paxlovid for the treatment of COVID-19 infection.